BRPI0508321A - hidróxi-6-heteroarilfenantridinas e seu uso como inibidores de pde4 - Google Patents
hidróxi-6-heteroarilfenantridinas e seu uso como inibidores de pde4Info
- Publication number
- BRPI0508321A BRPI0508321A BRPI0508321-4A BRPI0508321A BRPI0508321A BR PI0508321 A BRPI0508321 A BR PI0508321A BR PI0508321 A BRPI0508321 A BR PI0508321A BR PI0508321 A BRPI0508321 A BR PI0508321A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- substituted
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
Abstract
"HODRóXI-6-HETEROARILFENANTRIDINAS E SEU USO COMO INIBIDORES DE PDE4". Compostos da fórmula (I), na qual: R1é hidroxila, 1-4C-alcóxi, 3-7C-cicloalquilmetóxi, 2,2-difluoroetóxi ou 1-4C-alcóxi completa ou predominantemente flúor-substituído, R2é hidroxila, 1-4C-alcóxi, 3-7C-cicloalquilmetóxi, 2,2- difluoroetóxi ou 1-4C-alcóxi completa ou predominantemente flúor-substituído ou na qual: R1 e R2 juntos são um grupo 1-2C-alquilenodió, R3 é hidrogênio ou 1-4C-alquila, R31 é hidrogênio ou 1-4C alquila, ou em uma primeira modalidade (modalidade a) de acordo com a presente invenção, R4 é -O-R41, no qual: R41 é hidrogênio, 1-4C alquila, 1-4C alcóxi-14C-alquila, hidróxi-2-4C-alquila, 1-7C alquilcarbonila ou 1-4C-alquila completa ou predominantemente flúor-substituída e R5 é hidrogênio ou 1-4C alquila, ou em uma segunda modalidade (modalidade b) de acordo com a presente invenção, R4 é hidrogênio ou 1-4C- alquila e R5 é -O-R51, na qual R51 é hidrogênio, 1-4C-alquila, 1-4C-alcóxi-1-4C-alquila, hidroxi-2-4C-alquila, 1-7C-alquilcarbonila ou 1-4C-alquila completa ou predominantemente flíor-substituída, Har é opcionalmente substituído por R6 e/ou R7 e/ou R8 e é um radical heteroarila monocíclico ou bicíclico fundido insaturado ou parcialmente saturado de 5 a 10 elementos compreendendo 1 a 4 heteroátomos selecionados independentemente do grupo consistindo de oxigênio, nitrogênio e enxofre,são novos inibidores eficazes de PDE4.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004973 | 2004-03-03 | ||
EP04004973.6 | 2004-03-03 | ||
EP04106359.5 | 2004-12-07 | ||
EP04106359 | 2004-12-07 | ||
PCT/EP2005/050931 WO2005085225A1 (en) | 2004-03-03 | 2005-03-02 | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0508321A true BRPI0508321A (pt) | 2007-07-24 |
BRPI0508321B1 BRPI0508321B1 (pt) | 2018-02-06 |
Family
ID=34921303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508321-4A BRPI0508321B1 (pt) | 2004-03-03 | 2005-03-02 | Hidróxi-6-heteroarilfenantridinas, seu uso e composições farmacêuticas que as compreende |
Country Status (29)
Country | Link |
---|---|
US (8) | US8003798B2 (pt) |
EP (2) | EP1723135B1 (pt) |
JP (2) | JP4801039B2 (pt) |
KR (2) | KR101152488B1 (pt) |
CN (6) | CN104761545A (pt) |
AR (1) | AR049319A1 (pt) |
AU (1) | AU2005219576B2 (pt) |
BR (1) | BRPI0508321B1 (pt) |
CA (1) | CA2557752C (pt) |
CO (1) | CO5700749A2 (pt) |
CY (2) | CY1114319T1 (pt) |
DK (2) | DK1723135T5 (pt) |
EA (2) | EA014155B1 (pt) |
ES (2) | ES2427256T3 (pt) |
HK (4) | HK1207635A1 (pt) |
HR (2) | HRP20130828T1 (pt) |
IL (2) | IL177073A (pt) |
ME (1) | ME01955B (pt) |
MX (2) | MX341474B (pt) |
NO (2) | NO336538B1 (pt) |
NZ (1) | NZ549108A (pt) |
PL (2) | PL2589599T4 (pt) |
PT (2) | PT2589599E (pt) |
RS (2) | RS53543B1 (pt) |
SG (1) | SG182194A1 (pt) |
SI (2) | SI2589599T1 (pt) |
TW (2) | TWI404704B (pt) |
WO (1) | WO2005085225A1 (pt) |
ZA (1) | ZA200606176B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60311662T2 (de) | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
KR101152488B1 (ko) | 2004-03-03 | 2012-07-02 | 니코메드 게엠베하 | 신규 히드록시-6-헤테로아릴페난트리딘 및 pde4 억제제로서의 이의 용도 |
ES2342728T3 (es) | 2005-02-01 | 2010-07-13 | Nycomed Gmbh | Nuevas 6-piridilfenantridinas. |
EA200701815A1 (ru) * | 2005-03-02 | 2008-02-28 | Никомед Гмбх | 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний |
SI1856093T1 (sl) | 2005-03-02 | 2010-03-31 | Nycomed Gmbh | Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola |
US20100179131A1 (en) | 2006-09-07 | 2010-07-15 | Nycomed Gmbh | Combination treatment for diabetes mellitus |
US8013003B2 (en) * | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
WO2009025823A1 (en) * | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
JP2017503814A (ja) * | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のpde4インヒビターを用いた(およびロイコトリエン調節薬と組み合わせて用いた)治療 |
CN103936661B (zh) * | 2014-04-04 | 2016-08-24 | 常州大学 | 一种6-烷基菲啶衍生物的合成方法 |
JP2018521077A (ja) * | 2015-07-29 | 2018-08-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | 糖尿病性腎症を治療するためのpde4阻害剤 |
CN110099686B (zh) * | 2016-08-26 | 2022-04-15 | 武田药品工业株式会社 | 非酒精性脂肪性肝病的治疗 |
CN110573148A (zh) * | 2017-03-16 | 2019-12-13 | 武田有限公司 | 特发性肺纤维化的治疗 |
WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
EP3886854A4 (en) * | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
TWI785816B (zh) * | 2019-08-30 | 2022-12-01 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
TWI753296B (zh) * | 2019-08-30 | 2022-01-21 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
PT706513E (pt) | 1993-07-02 | 2002-10-31 | Byk Gulden Lomberg Chem Fab | Benzimidazois substituidos por fluoralcoxi e sua utilizacao como inibidores de fosfodiesterase nucleotidica ciclica |
US6191138B1 (en) | 1996-01-31 | 2001-02-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines |
US6127378A (en) | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
PT889886E (pt) | 1996-03-26 | 2003-02-28 | Altana Pharma Ag | Novas fenantridinas substituidas na posicao 6 |
JPH1020274A (ja) * | 1996-07-05 | 1998-01-23 | Fujitsu Ltd | 液晶表示駆動回路及び液晶表示装置 |
SK283269B6 (sk) | 1996-11-11 | 2003-04-01 | Altana Pharma Ag | Benzonaftyridíny, farmaceutický prostriedok s ich obsahom a ich použitie |
ATE248167T1 (de) | 1997-03-07 | 2003-09-15 | Altana Pharma Ag | Tetrazole derivate |
AU8106598A (en) | 1997-06-03 | 1998-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
US6214839B1 (en) | 1997-07-25 | 2001-04-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-alkylphenanthridines |
ES2189235T3 (es) | 1997-07-25 | 2003-07-01 | Altana Pharma Ag | 6-fenilfenantridinas sustituidas. |
US6410551B1 (en) | 1997-07-25 | 2002-06-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrazole derivatives |
CA2309175A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
ATE234301T1 (de) * | 1998-05-05 | 2003-03-15 | Altana Pharma Ag | Neue benzonaphtyridin-n-oxide |
US6436952B1 (en) | 1998-08-31 | 2002-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine-N-oxides comprising a PDE3 and PDE4 inhibiting activity |
ATE312081T1 (de) | 1999-01-15 | 2005-12-15 | Altana Pharma Ag | 6-phenylphenanthridine mit pde-iv hemmender wirkung |
JP2002534506A (ja) * | 1999-01-15 | 2002-10-15 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Pde−iv抑制作用を有する多重に置換された6−フェニルフェナントリジン |
AU2107700A (en) * | 1999-01-15 | 2000-08-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridine-n-oxides with pde-iv inhibiting activity |
SI1147103T1 (en) * | 1999-01-15 | 2005-10-31 | Altana Pharma Ag | Phenantrhridine-n-oxides with pde-iv inhibiting activity |
WO2000042019A1 (en) * | 1999-01-15 | 2000-07-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 6-arylphenanthridines with pde-iv inhibiting activity |
IL148807A0 (en) * | 1999-10-25 | 2002-09-12 | Byk Gulden Lomberg Chem Fab | Tetrahydrothiopyran derivatives and pharmaceutical compositions containing the same |
AU782908B2 (en) | 2000-01-11 | 2005-09-08 | Altana Pharma Ag | Phenanthridine-N-oxides |
EP1270577B1 (en) | 2000-03-23 | 2006-12-06 | Takeda Pharmaceutical Company Limited | Furoisoquinoline derivatives, process for producing the same and use thereof |
AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
AU2001267589A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines |
ES2236288T3 (es) * | 2000-07-14 | 2005-07-16 | Altana Pharma Ag | 6-heteroarilfenantridinas. |
CA2438717C (en) | 2001-02-21 | 2011-08-30 | Altana Pharma Ag | 6-phenylbenzonaphthyridines |
JP2005537312A (ja) | 2002-08-17 | 2005-12-08 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規のフェナントリジン |
EP1581533A2 (en) | 2002-08-17 | 2005-10-05 | ALTANA Pharma AG | Novel benzonaphthyridines |
ATE348616T1 (de) * | 2002-08-29 | 2007-01-15 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
DE60311662T2 (de) * | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
RU2247262C2 (ru) | 2003-05-19 | 2005-02-27 | Федеральное государственное унитарное предприятие Российский Федеральный Ядерный Центр-Всероссийский Научно-исследовательский институт технической физики им. акад. Е.И. Забабахина (РФЯЦ- ВНИИТФ) | Плунжерный насос сверхвысокого давления |
JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
AR049419A1 (es) | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
KR101152488B1 (ko) | 2004-03-03 | 2012-07-02 | 니코메드 게엠베하 | 신규 히드록시-6-헤테로아릴페난트리딘 및 pde4 억제제로서의 이의 용도 |
AU2005220034A1 (en) * | 2004-03-09 | 2005-09-15 | Nycomed Gmbh | Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
WO2005087745A1 (en) * | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
BRPI0508473A (pt) | 2004-03-10 | 2007-07-31 | Altana Pharma Ag | hidróxi-6-fenilfenantridinas contendo tiol e seu uso como inibidores de pde4 |
AU2005219581A1 (en) * | 2004-03-10 | 2005-09-15 | Nycomed Gmbh | Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
SI1856093T1 (sl) | 2005-03-02 | 2010-03-31 | Nycomed Gmbh | Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola |
-
2005
- 2005-03-02 KR KR1020117030419A patent/KR101152488B1/ko not_active IP Right Cessation
- 2005-03-02 ME MEP-2014-113A patent/ME01955B/me unknown
- 2005-03-02 CN CN201510101394.4A patent/CN104761545A/zh active Pending
- 2005-03-02 DK DK05716889.0T patent/DK1723135T5/da active
- 2005-03-02 CN CN201510101203.4A patent/CN104803974A/zh active Pending
- 2005-03-02 KR KR1020067019892A patent/KR101152439B1/ko not_active IP Right Cessation
- 2005-03-02 WO PCT/EP2005/050931 patent/WO2005085225A1/en active Application Filing
- 2005-03-02 AR ARP050100780 patent/AR049319A1/es not_active Application Discontinuation
- 2005-03-02 EP EP05716889.0A patent/EP1723135B1/en active Active
- 2005-03-02 AU AU2005219576A patent/AU2005219576B2/en not_active Ceased
- 2005-03-02 PL PL12196702T patent/PL2589599T4/pl unknown
- 2005-03-02 MX MX2011010146A patent/MX341474B/es unknown
- 2005-03-02 ES ES05716889T patent/ES2427256T3/es active Active
- 2005-03-02 PT PT12196702T patent/PT2589599E/pt unknown
- 2005-03-02 SG SG2012043295A patent/SG182194A1/en unknown
- 2005-03-02 JP JP2007501289A patent/JP4801039B2/ja not_active Expired - Fee Related
- 2005-03-02 NZ NZ549108A patent/NZ549108A/en unknown
- 2005-03-02 CN CN201510100429.2A patent/CN104817534A/zh active Pending
- 2005-03-02 SI SI200531890T patent/SI2589599T1/sl unknown
- 2005-03-02 MX MXPA06009695A patent/MXPA06009695A/es active IP Right Grant
- 2005-03-02 SI SI200531772T patent/SI1723135T1/sl unknown
- 2005-03-02 PT PT57168890T patent/PT1723135E/pt unknown
- 2005-03-02 CN CN2011101613875A patent/CN102295634A/zh active Pending
- 2005-03-02 EA EA200601568A patent/EA014155B1/ru not_active IP Right Cessation
- 2005-03-02 CN CNA2005800057687A patent/CN1922170A/zh active Pending
- 2005-03-02 ES ES12196702.0T patent/ES2505473T3/es active Active
- 2005-03-02 RS RSP20140498 patent/RS53543B1/en unknown
- 2005-03-02 US US10/590,803 patent/US8003798B2/en active Active
- 2005-03-02 PL PL05716889T patent/PL1723135T3/pl unknown
- 2005-03-02 EA EA201000494A patent/EA017282B1/ru not_active IP Right Cessation
- 2005-03-02 CN CN201510100383.4A patent/CN104803973A/zh active Pending
- 2005-03-02 RS RS20130349A patent/RS52916B/en unknown
- 2005-03-02 EP EP20120196702 patent/EP2589599B1/en active Active
- 2005-03-02 CA CA2557752A patent/CA2557752C/en not_active Expired - Fee Related
- 2005-03-02 BR BRPI0508321-4A patent/BRPI0508321B1/pt not_active IP Right Cessation
- 2005-03-02 DK DK12196702T patent/DK2589599T3/da active
- 2005-03-03 TW TW100110218A patent/TWI404704B/zh not_active IP Right Cessation
- 2005-03-03 TW TW094106493A patent/TWI372750B/zh not_active IP Right Cessation
-
2006
- 2006-07-25 IL IL177073A patent/IL177073A/en not_active IP Right Cessation
- 2006-07-26 ZA ZA200606176A patent/ZA200606176B/xx unknown
- 2006-07-28 CO CO06074146A patent/CO5700749A2/es active IP Right Grant
- 2006-09-19 NO NO20064221A patent/NO336538B1/no not_active IP Right Cessation
-
2011
- 2011-01-21 JP JP2011011310A patent/JP5193320B2/ja active Active
- 2011-05-19 US US13/111,544 patent/US8324391B2/en active Active
- 2011-05-19 US US13/111,524 patent/US8318944B2/en not_active Expired - Fee Related
-
2012
- 2012-08-06 IL IL221323A patent/IL221323A0/en not_active IP Right Cessation
- 2012-10-26 US US13/661,897 patent/US8455653B2/en not_active Expired - Fee Related
-
2013
- 2013-04-30 US US13/873,670 patent/US8883818B2/en not_active Expired - Fee Related
- 2013-09-05 HR HRP20130828TT patent/HRP20130828T1/hr unknown
- 2013-09-09 CY CY20131100770T patent/CY1114319T1/el unknown
-
2014
- 2014-09-08 CY CY20141100722T patent/CY1115536T1/el unknown
- 2014-09-17 HR HRP20140892TT patent/HRP20140892T1/hr unknown
- 2014-10-07 US US14/508,077 patent/US9149479B2/en not_active Expired - Fee Related
- 2014-12-18 NO NO20141541A patent/NO338326B1/no not_active IP Right Cessation
-
2015
- 2015-08-25 US US14/834,709 patent/US9387205B2/en not_active Expired - Fee Related
- 2015-08-26 HK HK15108262.7A patent/HK1207635A1/xx unknown
- 2015-09-16 HK HK15109032.4A patent/HK1208447A1/xx unknown
- 2015-09-30 HK HK15109596.2A patent/HK1208865A1/xx unknown
-
2016
- 2016-01-18 HK HK16100490.7A patent/HK1214812A1/zh unknown
- 2016-06-10 US US15/179,268 patent/US9962377B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508321A (pt) | hidróxi-6-heteroarilfenantridinas e seu uso como inibidores de pde4 | |
WO2005087745A8 (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
AR062427A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
EA200701114A1 (ru) | Азоловые производные с антимускариновой активностью | |
BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
PE20090511A1 (es) | Imidazopiridinonas | |
AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
PE20110153A1 (es) | Derivados de piridazina como inhibidores de smo | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
PE20060573A1 (es) | Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas | |
WO2005087744A8 (en) | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
AR073116A1 (es) | Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
PE20071020A1 (es) | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa | |
PE20051094A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico y procesos para su preparacion | |
PE20090902A1 (es) | Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
ECSP077998A (es) | Moduladores de cinasa de aminoquinolina y aminoquinazolina | |
ECSP077991A (es) | Aminopirimidinas como moduladores de cinasa | |
ECSP088965A (es) | Derivados de 2-tioxantina que actúan como inhibidores de la mpo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: NYCOMED GMBH (DE) Free format text: ALTERADO DE: ALTANA PHARMA AG |
|
B25D | Requested change of name of applicant approved |
Owner name: TAKEDA GMBH (DE) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: NYCOMED ASSET MANAGEMENT GMBH (DE) |
|
B25A | Requested transfer of rights approved |
Owner name: NYCOMED GERMANY HOLDING GMBH (DE) |
|
B25D | Requested change of name of applicant approved |
Owner name: TAKEDA GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2556 DE 2019-12-31 |